Elaine W Flagg1, Elizabeth A Torrone1, Hillard Weinstock1. 1. At the time of the study, all of the authors were with the Division of STD Prevention; National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention; Centers for Disease Control and Prevention; Atlanta, GA.
Abstract
OBJECTIVES: To examine prevalence of low- and high-grade cervical lesions over time in a large cohort of US female adolescents and women. METHODS: We used health care claims data from 9 million privately insured female patients aged 15 to 39 years to estimate annual prevalence of cytologically detected cervical low-grade (LSIL) and high-grade squamous intraepithelial lesions (HSIL) and high-grade histologically detected cervical intraepithelial neoplasia grades 2 and 3 (CIN2+) during 2007 through 2014. We restricted analyses to those who received cervical cancer screening in a given calendar year. RESULTS: Prevalence of HSIL and CIN2+ decreased significantly for those aged 15 to 19 years. Average annual percent change in prevalence in this group during 2007 through 2014 for HSIL and CIN2+ was -8.3% and -14.4%, respectively (P < .001 for both estimates). Prevalence of HSIL and CIN2+ also decreased significantly for women aged 20 to 24 years. No decreases were seen in women aged 25 to 39 years. CONCLUSIONS: Decreases in high-grade lesions reflected their greater association with human papillomavirus types 16 and 18, compared with low-grade lesions, providing ecological evidence of population effectiveness of human papillomavirus vaccination among young, privately insured women.
OBJECTIVES: To examine prevalence of low- and high-grade cervical lesions over time in a large cohort of US female adolescents and women. METHODS: We used health care claims data from 9 million privately insured female patients aged 15 to 39 years to estimate annual prevalence of cytologically detected cervical low-grade (LSIL) and high-grade squamous intraepithelial lesions (HSIL) and high-grade histologically detected cervical intraepithelial neoplasia grades 2 and 3 (CIN2+) during 2007 through 2014. We restricted analyses to those who received cervical cancer screening in a given calendar year. RESULTS: Prevalence of HSIL and CIN2+ decreased significantly for those aged 15 to 19 years. Average annual percent change in prevalence in this group during 2007 through 2014 for HSIL and CIN2+ was -8.3% and -14.4%, respectively (P < .001 for both estimates). Prevalence of HSIL and CIN2+ also decreased significantly for women aged 20 to 24 years. No decreases were seen in women aged 25 to 39 years. CONCLUSIONS: Decreases in high-grade lesions reflected their greater association with human papillomavirus types 16 and 18, compared with low-grade lesions, providing ecological evidence of population effectiveness of human papillomavirus vaccination among young, privately insured women.
Authors: Lauri E Markowitz; Susan Hariri; Elizabeth R Unger; Mona Saraiya; S Deblina Datta; Eileen F Dunne Journal: Vaccine Date: 2010-02-25 Impact factor: 3.641
Authors: Mona Saraiya; Elizabeth R Unger; Trevor D Thompson; Charles F Lynch; Brenda Y Hernandez; Christopher W Lyu; Martin Steinau; Meg Watson; Edward J Wilkinson; Claudia Hopenhayn; Glenn Copeland; Wendy Cozen; Edward S Peters; Youjie Huang; Maria Sibug Saber; Sean Altekruse; Marc T Goodman Journal: J Natl Cancer Inst Date: 2015-04-29 Impact factor: 13.506
Authors: Julia M L Brotherton; Masha Fridman; Cathryn L May; Genevieve Chappell; A Marion Saville; Dorota M Gertig Journal: Lancet Date: 2011-06-18 Impact factor: 79.321
Authors: Rachel L Winer; Nancy B Kiviat; James P Hughes; Diane E Adam; Shu-Kuang Lee; Jane M Kuypers; Laura A Koutsky Journal: J Infect Dis Date: 2005-01-21 Impact factor: 5.226
Authors: Suzanne M Garland; Mauricio Hernandez-Avila; Cosette M Wheeler; Gonzalo Perez; Diane M Harper; Sepp Leodolter; Grace W K Tang; Daron G Ferris; Marc Steben; Janine Bryan; Frank J Taddeo; Radha Railkar; Mark T Esser; Heather L Sings; Micki Nelson; John Boslego; Carlos Sattler; Eliav Barr; Laura A Koutsky Journal: N Engl J Med Date: 2007-05-10 Impact factor: 91.245
Authors: Thomas C Wright; L Stewart Massad; Charles J Dunton; Mark Spitzer; Edward J Wilkinson; Diane Solomon Journal: Am J Obstet Gynecol Date: 2007-10 Impact factor: 8.661
Authors: John Doorbar; Wim Quint; Lawrence Banks; Ignacio G Bravo; Mark Stoler; Tom R Broker; Margaret A Stanley Journal: Vaccine Date: 2012-11-20 Impact factor: 3.641
Authors: Sarah Reagan-Steiner; David Yankey; Jenny Jeyarajah; Laurie D Elam-Evans; James A Singleton; C Robinette Curtis; Jessica MacNeil; Lauri E Markowitz; Shannon Stokley Journal: MMWR Morb Mortal Wkly Rep Date: 2015-07-31 Impact factor: 17.586
Authors: Michael J Silverberg; Wendy A Leyden; Jennifer O Lam; Steven E Gregorich; Megan J Huchko; Shalini Kulasingam; Miriam Kuppermann; Karen K Smith-McCune; George F Sawaya Journal: Lancet Child Adolesc Health Date: 2018-08-08
Authors: Julia Warner Gargano; Ina U Park; Marie R Griffin; Linda M Niccolai; Melissa Powell; Nancy M Bennett; Michelle L Johnson Jones; Erin Whitney; Manideepthi Pemmaraju; Monica Brackney; Nasreen Abdullah; Mary Scahill; Rebecca M Dahl; Angela A Cleveland; Elizabeth R Unger; Lauri E Markowitz Journal: Clin Infect Dis Date: 2019-04-08 Impact factor: 9.079
Authors: Nancy M McClung; Julia W Gargano; Nancy M Bennett; Linda M Niccolai; Nasreen Abdullah; Marie R Griffin; Ina U Park; Angela A Cleveland; Troy D Querec; Elizabeth R Unger; Lauri E Markowitz Journal: Cancer Epidemiol Biomarkers Prev Date: 2019-02-21 Impact factor: 4.254
Authors: Sara E Oliver; Elizabeth R Unger; Rayleen Lewis; Darius McDaniel; Julia W Gargano; Martin Steinau; Lauri E Markowitz Journal: J Infect Dis Date: 2017-09-01 Impact factor: 5.226
Authors: Jaimie Z Shing; Marie R Griffin; Rachel S Chang; Alicia Beeghly-Fadiel; Staci L Sudenga; James C Slaughter; Manideepthi Pemmaraju; Edward F Mitchel; Pamela C Hull Journal: Am J Prev Med Date: 2021-10-29 Impact factor: 5.043